Bulis Veronica Sanchez

VP, Corporate ControllerLyell Immunopharma, Inc. (LYEL) · full profile →Form 4 · filed Jun 15, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$4K
Net Open-Market Flow
-$4K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 11, 2026Sell(S)217$18.91$4K15K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002095702-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly: